JP2010540660A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540660A5
JP2010540660A5 JP2010528167A JP2010528167A JP2010540660A5 JP 2010540660 A5 JP2010540660 A5 JP 2010540660A5 JP 2010528167 A JP2010528167 A JP 2010528167A JP 2010528167 A JP2010528167 A JP 2010528167A JP 2010540660 A5 JP2010540660 A5 JP 2010540660A5
Authority
JP
Japan
Prior art keywords
antibody
mammal
composition
administration
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010528167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540660A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/078769 external-priority patent/WO2009046313A2/en
Publication of JP2010540660A publication Critical patent/JP2010540660A/ja
Publication of JP2010540660A5 publication Critical patent/JP2010540660A5/ja
Pending legal-status Critical Current

Links

JP2010528167A 2007-10-05 2008-10-03 哺乳類内の赤血球生成を刺激する新規の組成物および方法 Pending JP2010540660A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99781807P 2007-10-05 2007-10-05
PCT/US2008/078769 WO2009046313A2 (en) 2007-10-05 2008-10-03 Novel compositions and methods for stimulating erythropoiesis in a mammal

Publications (2)

Publication Number Publication Date
JP2010540660A JP2010540660A (ja) 2010-12-24
JP2010540660A5 true JP2010540660A5 (enExample) 2011-11-17

Family

ID=40526962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528167A Pending JP2010540660A (ja) 2007-10-05 2008-10-03 哺乳類内の赤血球生成を刺激する新規の組成物および方法

Country Status (5)

Country Link
US (1) US20100203047A1 (enExample)
EP (1) EP2195344A4 (enExample)
JP (1) JP2010540660A (enExample)
CA (1) CA2701608A1 (enExample)
WO (1) WO2009046313A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163506A2 (en) * 2010-06-23 2011-12-29 University Of Louisville Research Foundation, Inc. Methods and kits for predicting a response to an erythropoietic agent
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
HRP20230675T1 (hr) 2017-08-03 2023-09-29 Alector Llc Anti-trem2 protutijela i postupci njihove uporabe

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
WO1998051346A1 (en) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Human tumor necrosis factor receptor-like 2 (tr2) antibodies
EP1169352A4 (en) * 1999-04-14 2005-05-04 Smithkline Beecham Corp ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
EP1336619A3 (en) * 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
WO2003086301A2 (en) * 2002-04-12 2003-10-23 Human Genome Sciences, Inc. Antibodies that specifically bind to tr2
WO2007001459A2 (en) * 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
AU2003300184B8 (en) * 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
MX2007005612A (es) * 2004-11-12 2007-08-14 Genentech Inc Novedosas composiciones y metodos para el tratamiento de enfermedades inmuno relacionadas.
JP2009533057A (ja) * 2006-04-14 2009-09-17 アムジエン・インコーポレーテツド エリスロポエチン受容体アゴニスト
WO2008146101A1 (en) * 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases

Similar Documents

Publication Publication Date Title
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
US20140212423A1 (en) Blood-brain barrier penetrating dual specific binding proteins
CN111630070A (zh) 三特异性蛋白质及使用方法
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2020522513A5 (enExample)
JP2018535948A5 (enExample)
JP2010526028A5 (enExample)
TW202210507A (zh) 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
JP2014527814A5 (enExample)
FI3569620T3 (fi) Ihmisen cgrp-reseptoria sitovat vasta-aineet
JP7459058B2 (ja) Cd137/her2二重特異性物質とpd-1系阻害物質とを含む併用療法およびその使用法
CN105324396A (zh) 针对IL-1β和/或IL-17的双重特异性结合蛋白
JP2019510739A5 (enExample)
JP2014502955A5 (enExample)
US20220017617A1 (en) Efficiently expressed egfr and pd-l1 bispecific binding proteins
WO2014149733A1 (en) Pan-ELR+ CXC CHEMOKINE ANTIBODIES
JP2020502219A5 (enExample)
WO2018067819A1 (en) Compositions and methods for treatment of cancers
JP6933724B2 (ja) Nk細胞活性化融合タンパク質、nk細胞およびそれらを含む医薬組成物
JP2018512402A5 (enExample)
CN109152814A (zh) 方法、方案、组合和拮抗剂
HRP20161096T1 (hr) Antigenski vežući proteini specifični za komponentu p serumskog amiloida
US20150110788A1 (en) Bispecific antibodies with an fgf2 binding domain
JP2010540660A5 (enExample)
JP2020502218A5 (enExample)